EcoR1 Capital PHVS Position
Exited7-Fund ConvergenceEcoR1 Capital exited their position in Pharvaris N.V. (PHVS) in Q4 2024, after holding the stock for 5 quarters.
The position was first reported in Q4 2023 and has been tracked across 5 quarterly 13F filings.
PHVS is a convergence signal: 7 specialist biotech funds hold this stock, suggesting high institutional conviction.
About Pharvaris N.V.
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients and is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is based in Leiden, the Netherlands.
Full company profile →Short Interest
1.4%
6.0 days to cover
EcoR1 Capital PHVS Position History
Frequently Asked Questions
Does EcoR1 Capital own PHVS?
No. EcoR1 Capital exited their position in Pharvaris N.V. (PHVS) in Q4 2024. They previously held the stock for 5 quarters.
How many hedge funds own PHVS?
7 specialist biotech hedge funds currently hold PHVS, including Foresite Capital, Deerfield Management, Commodore Capital and 4 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did EcoR1 Capital first buy PHVS?
EcoR1 Capital's position in PHVS was first reported in Q4 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is EcoR1 Capital's PHVS position increasing or decreasing?
EcoR1 Capital completely exited their PHVS position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
PHVSCompany Page →
All fund holders, insider trades, catalysts, and cash runway
EcoR1 CapitalPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →